cilostazol has been researched along with pentoxifylline in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 38 (60.32) | 29.6817 |
| 2010's | 17 (26.98) | 24.3611 |
| 2020's | 6 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
| Bradley, DV; Britt, KE; Charles, BE; Dawson, DL; DeMaioribus, CA; Hagino, RT; Light, JT | 1 |
| Carman, TL; Fernandez, BB | 1 |
| Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M | 1 |
| Bortey, EB; Cutler, BS; Dawson, DL; Forbes, WP; Hiatt, WR; Hobson, RW; Martin, JD; Strandness, DE | 1 |
| Weismantel, D | 1 |
| Riemann, LE; Tjon, JA | 1 |
| Cariski, AT | 1 |
| Hiatt, WR | 1 |
| Beebe, HG | 1 |
| Dawson, DL | 1 |
| Pratt, CM | 1 |
| Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS | 1 |
| Chen, MF; Hwang, JJ; Lee, TM; Lee, YT; Su, SF; Tseng, CD; Wang, SS | 1 |
| Hiatt, WR; Regensteiner, JG | 1 |
| Cariski, AT; Lindmayer, K | 1 |
| Doggrell, SA | 1 |
| Fernandez, BB | 1 |
| Anand, S; Creager, M | 3 |
| Olin, JW | 1 |
| Conners, MS; Money, SR | 1 |
| Forbes, WP; Thompson, PD; Zhang, P; Zimet, R | 1 |
| Elam, MB; Forbes, WP; Nakajima, K; Wang, T; Zhong, J | 1 |
| Landi, A | 1 |
| Jacoby, D; Mohler, ER | 1 |
| Brittenden, J; Collins, P | 1 |
| Bachoo, P | 2 |
| Clegg, JP; Davie, AM; Guest, JF | 1 |
| Kim, DH | 1 |
| Regensteiner, JG; Stewart, KJ | 1 |
| Kim, S; Lipsitz, EC | 1 |
| Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA | 1 |
| Dobesh, PP; Persson, EL; Stacy, ZA | 1 |
| Huisinga, JM; Johanning, JM; Pipinos, II; Stergiou, N | 2 |
| Olin, JW; Sealove, BA | 1 |
| Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, J; Thomas, S; Wong, R | 1 |
| Bredarioli, M; Dalio, MB; do Prado, WA; Joviliano, EE; Piccinato, CE | 1 |
| Huisinga, JM; Johanning, JM; Myers, SA; Pipinos, II; Stergiou, N; Yentes, JM | 1 |
| Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S | 1 |
| Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S | 1 |
| Melzer, J; Saller, R | 1 |
| Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M | 1 |
| Agrawal, K; Eberhardt, RT | 1 |
| Claus, PL; Domecq, JP; Elraiyah, T; Firwana, B; Hasan, R; Hingorani, A; Murad, MH; Nabhan, M; Prokop, L; Prutsky, G; Steinkraus, LW; Tsapas, A | 1 |
| Kibbe, MR; McDermott, MM | 1 |
| Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC | 1 |
| Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA | 1 |
| Erofeeva, SB; Ershova, OB; Goriunov, SV; Gurgenian, EV; Kazantsev, AN | 1 |
| Abdel-Razek, NS; Salem, HA; Wadie, W | 1 |
| Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M | 1 |
| Cao, Y; Liang, X; Wang, Y; Zhao, C | 1 |
| Amin, A; Habib, HA; Heeba, GH; Othman, EM; Zahran, ME | 1 |
30 review(s) available for cilostazol and pentoxifylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A primary care approach to the patient with claudication.
Topics: Arterial Occlusive Diseases; Cilostazol; Exercise; Humans; Patient Education as Topic; Pentoxifylline; Platelet Aggregation Inhibitors; Primary Health Care; Pulse; Risk Factors; Severity of Illness Index; Teaching Materials; Tetrazoles; Vasodilator Agents | 2000 |
Treatment of intermittent claudication with pentoxifylline and cilostazol.
Topics: Aged; Area Under Curve; Cilostazol; Drug Interactions; Exercise Therapy; Humans; Intermittent Claudication; Middle Aged; Pentoxifylline; Randomized Controlled Trials as Topic; Tetrazoles; Vasodilator Agents | 2001 |
Cilostazol: a novel treatment option in intermittent claudication.
Topics: Cilostazol; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Intermittent Claudication; Multicenter Studies as Topic; Pentoxifylline; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; United Kingdom; United States | 2001 |
New treatment options in intermittent claudication: the US experience.
Topics: Arginine; Carnitine; Cilostazol; Endothelial Growth Factors; Exercise Therapy; Humans; Intermittent Claudication; Multicenter Studies as Topic; Nafronyl; Pentoxifylline; Phosphodiesterase Inhibitors; Prostaglandins; Quality of Life; Randomized Controlled Trials as Topic; Serotonin Antagonists; Tetrazoles; United States | 2001 |
Intermittent claudication: effective medical management of a common circulatory problem.
Topics: Angioplasty; Cilostazol; Diagnosis, Differential; Exercise Therapy; Humans; Intermittent Claudication; Patient Education as Topic; Pentoxifylline; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Vasodilator Agents | 2001 |
Comparative effects of cilostazol and other therapies for intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Vasodilator Agents | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus; Estrogens; Exercise; Homocysteine; Humans; Hyperlipidemias; Hypertension; Intermittent Claudication; Meta-Analysis as Topic; Myocardial Ischemia; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tetrazoles | 2002 |
Pharmacotherapy of intermittent claudication.
Topics: Animals; Anticoagulants; Cardiotonic Agents; Carnitine; Cilostazol; Humans; Intermittent Claudication; Nafronyl; Nitric Oxide; Pentoxifylline; Platelet Aggregation Inhibitors; Tetrazoles; Vasodilator Agents | 2001 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combined Modality Therapy; Exercise; Humans; Infant, Newborn; Pentoxifylline; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Tetrazoles; Treatment Outcome | 2002 |
Management of patients with intermittent claudication.
Topics: Aspirin; Blood Vessel Prosthesis; Cilostazol; Clopidogrel; Exercise Therapy; Humans; Intermittent Claudication; Medical History Taking; Pentoxifylline; Physical Examination; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Vasodilator Agents | 2002 |
Can claudication be improved with medication?
Topics: Carnitine; Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Platelet Aggregation Inhibitors; Prostaglandins; Tetrazoles; Ticlopidine; Vasodilator Agents | 2002 |
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
Topics: Aged; Cholesterol, HDL; Cilostazol; Clinical Trials, Phase III as Topic; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Multicenter Studies as Topic; Pentoxifylline; Phosphodiesterase Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Triglycerides; Vasodilator Agents; Walking | 2002 |
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematologic Agents; Hemodilution; Hemorheology; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Intermittent Claudication; Nafronyl; Pentoxifylline; Platelet Aggregation Inhibitors; Pyrrolidines; Risk Factors; Smoking; Tetrazoles; Vasodilator Agents; Walking | 2004 |
Drug treatment of intermittent claudication.
Topics: Animals; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Pentoxifylline; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Cilostazol; Combined Modality Therapy; Exercise; Humans; Infant, Newborn; Pentoxifylline; Platelet Aggregation Inhibitors; Risk Factors; Smoking Cessation; Tetrazoles | 2002 |
Treatment of intermittent claudication: cilostazol.
Topics: Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudication; Pentoxifylline; Tetrazoles; Vasodilator Agents; Walking | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Smoking Cessation; Tetrazoles | 2003 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Smoking Cessation; Tetrazoles | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Coronary Artery Bypass; Exercise; Humans; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Smoking Cessation; Tetrazoles | 2004 |
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exercise Therapy; Hematologic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tetrazoles; Vasodilator Agents | 2006 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; Guidelines as Topic; Humans; Intermittent Claudication; Meta-Analysis as Topic; Nafronyl; Pentoxifylline; Peripheral Vascular Diseases; Pyrrolidines; Risk Factors; Tetrazoles; Treatment Outcome | 2009 |
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Nicotinic Acids; Pentoxifylline; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Tetrazoles; United Kingdom; Vasodilator Agents | 2011 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Vasodilator Agents; Walking | 2012 |
[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
Topics: Arterial Occlusive Diseases; Cilostazol; Complementary Therapies; Humans; Intermittent Claudication; Medicine, Tibetan Traditional; Nafronyl; Pentoxifylline; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Tetrazoles; Triglycerides; Walking | 2013 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Walking | 2014 |
Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication.
Topics: Ankle Brachial Index; Cilostazol; Combined Modality Therapy; Exercise Therapy; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Arterial Disease; Risk Reduction Behavior; Symptom Assessment; Tetrazoles | 2015 |
A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers.
Topics: Aged; Cilostazol; Diabetic Foot; Female; Humans; Hyperbaric Oxygenation; Iloprost; Male; Middle Aged; Pentoxifylline; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2016 |
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifylline; Peripheral Vascular Diseases; Placebos; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Walking | 2021 |
Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
Topics: Cilostazol; Humans; Intermittent Claudication; Network Meta-Analysis; Pentoxifylline; Randomized Controlled Trials as Topic; Vasodilator Agents | 2022 |
7 trial(s) available for cilostazol and pentoxifylline
| Article | Year |
|---|---|
The effect of withdrawal of drugs treating intermittent claudication.
Topics: Administration, Oral; Adult; Aged; Cilostazol; Cross-Over Studies; Double-Blind Method; Exercise Test; Female; Follow-Up Studies; Humans; Intermittent Claudication; Male; Middle Aged; Pentoxifylline; Placebos; Platelet Aggregation Inhibitors; Single-Blind Method; Tetrazoles; Treatment Outcome; Vasodilator Agents; Walking | 1999 |
A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
Topics: Aged; Cilostazol; Double-Blind Method; Drug Administration Schedule; Exercise Test; Female; Humans; Intermittent Claudication; Male; Middle Aged; Pentoxifylline; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome; Vasodilator Agents; Walking | 2000 |
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Double-Blind Method; Endothelial Growth Factors; Exercise Tolerance; Female; Humans; Intermittent Claudication; Lymphokines; Male; Middle Aged; Pentoxifylline; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Prospective Studies; Tetrazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents | 2001 |
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hypolipidemic Agents; Interleukin-6; Intermittent Claudication; Lipids; Male; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Tetrazoles; Triglycerides; Vasodilator Agents | 2001 |
Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
Topics: Aged; Cholesterol; Cilostazol; Female; Follow-Up Studies; Humans; Intermittent Claudication; Lipoproteins; Male; Middle Aged; Pentoxifylline; Probability; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
Topics: Aged; Analgesics; Cilostazol; Gait; Gait Disorders, Neurologic; Humans; Intermittent Claudication; Male; Neuroprotective Agents; Pentoxifylline; Phosphodiesterase Inhibitors; Tetrazoles; Treatment Outcome | 2012 |
[Randomized study of tolerability, safety and efficacy of Pletax in intermittent claudication].
Topics: Adult; Aged; Cilostazol; Exercise Test; Humans; Intermittent Claudication; Middle Aged; Pentoxifylline; Walking | 2021 |
26 other study(ies) available for cilostazol and pentoxifylline
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans; Intermittent Claudication; Male; Milrinone; Myocardial Ischemia; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Tetrazoles; Thioinosine | 2000 |
Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?
Topics: Cilostazol; Evidence-Based Medicine; Humans; Intermittent Claudication; Pentoxifylline; Tetrazoles; Time Factors; Treatment Outcome; Vasodilator Agents; Walking | 2001 |
A new treatment for peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Tetrazoles | 2001 |
Analysis of the cilostazol safety database.
Topics: Adverse Drug Reaction Reporting Systems; Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Vasodilator Agents | 2001 |
Cilostazol in intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Phosphodiesterase Inhibitors; Quality of Life; Tetrazoles; Walking | 2002 |
A rational approach to diagnosis and treatment of intermittent claudication.
Topics: Algorithms; Blood Pressure Determination; Cilostazol; Disease Progression; Exercise Test; Hematologic Agents; Humans; Intermittent Claudication; Medical History Taking; Pentoxifylline; Physical Examination; Risk Factors; Surveys and Questionnaires; Tetrazoles; Vascular Surgical Procedures; Vasodilator Agents | 2002 |
[Peripheral arterial occlusive disease (PAVK)].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Arteries; Cilostazol; Evidence-Based Medicine; Exercise; Humans; Intermittent Claudication; Leg; Pentoxifylline; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Smoking Cessation; Tetrazoles | 2003 |
Drugs for intermittent claudication.
Topics: Cilostazol; Diabetes Complications; Exercise Therapy; Female; Ginkgo biloba; Humans; Hyperlipidemias; Intermittent Claudication; Male; Pentoxifylline; Phosphodiesterase Inhibitors; Phytotherapy; Plant Extracts; Platelet Aggregation Inhibitors; Risk Factors; Smoking; Tetrazoles | 2004 |
Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Topics: Adult; Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; State Medicine; Tetrazoles; United Kingdom; Vasodilator Agents; Walking | 2005 |
Exercise and peripheral arterial disease.
Topics: Cilostazol; Exercise Therapy; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Tetrazoles; Walking | 2006 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathies; Humans; Hypertension; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Risk Factors; Smoking; Tetrazoles; Thrombolytic Therapy; Ticlopidine | 2008 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pentoxifylline; Peritoneum; Phosphodiesterase Inhibitors; Surgical Sponges; Tetrazoles; Tissue Adhesions | 2009 |
The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.
Topics: Aged; Biomechanical Phenomena; Cardiovascular Agents; Case-Control Studies; Cilostazol; Dyskinesias; Female; Gait; Humans; Leg; Male; Middle Aged; Pentoxifylline; Peripheral Vascular Diseases; Range of Motion, Articular; Tetrazoles; Time Factors; Treatment Outcome; Walking | 2010 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progression; Fibrinolytic Agents; Humans; Intermittent Claudication; Magnetic Resonance Angiography; Mass Screening; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Risk Reduction Behavior; Tetrazoles; Tomography, X-Ray Computed; Ultrasonography, Doppler, Duplex; United States; Vasodilator Agents | 2010 |
Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Cilostazol; Female; Gait; Humans; Imaging, Three-Dimensional; Intermittent Claudication; Male; Pain Measurement; Pentoxifylline; Peripheral Vascular Diseases; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2010 |
Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb.
Topics: Animals; Biomechanical Phenomena; Cilostazol; Gait; Hindlimb; Ischemia; Male; Pentoxifylline; Rats; Rats, Wistar; Tetrazoles; Vasodilator Agents | 2012 |
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Intermittent Claudication; Markov Chains; Nafronyl; Pentoxifylline; Peripheral Arterial Disease; Tetrazoles; Vasodilator Agents | 2014 |
Improving Lower Extremity Functioning in Peripheral Artery Disease: Exercise, Endovascular Revascularization, or Both?
Topics: Adult; Cilostazol; Combined Modality Therapy; Endovascular Procedures; Exercise Test; Exercise Therapy; Humans; Intermittent Claudication; Lower Extremity; Pentoxifylline; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Tetrazoles; Vasodilator Agents; Walking | 2017 |
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol; Databases, Factual; Drug Interactions; Electronic Health Records; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Patient Safety; Pentoxifylline; Peripheral Arterial Disease; Phosphodiesterase 3 Inhibitors; Polypharmacy; Primary Health Care; Retrospective Studies; Risk Assessment; Risk Factors; Spain; Time Factors; Treatment Outcome | 2018 |
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Wistar; Sildenafil Citrate; Triglycerides | 2020 |
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Topics: Acute Kidney Injury; Animals; Blood Urea Nitrogen; Cilostazol; Creatinine; Diclofenac; Kidney; Male; NF-kappa B; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Wistar; Sildenafil Citrate; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vinca Alkaloids | 2021 |
Mechanistic Protective Effect of Cilostazol in Cisplatin-Induced Testicular Damage via Regulation of Oxidative Stress and TNF-α/NF-κB/Caspase-3 Pathways.
Topics: Animals; Caspase 3; Cilostazol; Cisplatin; Inflammation; Male; NF-kappa B; Oxidative Stress; Pentoxifylline; Phosphodiesterase 3 Inhibitors; Rats; Semen; Tadalafil; Tumor Necrosis Factor-alpha | 2023 |